| |
The severe group
|
The non-severe group
|
F/T
|
P
|
|---|
|
mMRC scorea
|
N = 22
|
N = 34
| | |
|
0
|
5 (22.7%)
|
11 (32.4%)
|
4.785
|
0.310
|
|
1
|
11 (50.0%)
|
12 (35.3%)
| | |
|
2
|
3 (13.6%)
|
10 (29.4%)
| | |
|
3
|
3 (13.6%)
|
1 (2.9%)
| | |
|
Pulmonary function parametersb
|
N = 21
|
N = 31
| | |
|
FVC (L)
|
3.10 ± 0.59
|
3.52 ± 0.6
|
− 2.517
|
0.015
|
|
FVC (%)
|
101.41 ± 14.52
|
104.69 ± 13.30
|
0.835
|
0.408
|
|
FVC% < 80%
|
0
|
0
|
–
|
–
|
|
FEV1(L)
|
2.48 ± 0.514
|
2.90 ± 0.453
|
3.313
|
0.003
|
|
FEV1 (%)
|
95.21 ± 12.46
|
101.61 ± 12.66
|
1.604
|
0.108
|
|
FEV1% < 80%
|
4 (19.0%)
|
0
|
6.397
|
0.011
|
|
FEV1/FVC (%)
|
79.23 ± 4.35
|
82.64 ± 4.80
|
2.611
|
0.012
|
|
FEV1/FVC < 70%
|
1 (4.8%)
|
0
|
1.505
|
0.220
|
|
DLCO (mmol/min/KPa)
|
6.86 ± 1.31
|
7.18 ± 1.43
|
0.807
|
0.424
|
|
DLCO (%)
|
84.01 ± 11.06
|
82.18 ± 12.42
|
− 0.563
|
0.576
|
|
DLCO% < 80%
|
6 (28.6%)
|
13 (41.9%)
|
0.964
|
0.326
|
|
TLC (L)
|
5.05 ± 0.87
|
5.39 ± 0.71
|
1.599
|
0.116
|
|
TLC (%)
|
100.32 ± 10.83
|
103.93 ± 9.37
|
1.277
|
0.207
|
|
TLC% < 80%
|
0
|
0
|
–
|
–
|
|
RV/TLC (%)
|
38.69 ± 5.86
|
37.23 ± 5.77
|
− 0.889
|
0.378
|
|
RV (%)
|
107.73 ± 13.66
|
111.70 ± 17.22
|
0.884
|
0.381
|
|
RV% > 120%
|
6 (28.6%)
|
12 (38.7%)
|
0.569
|
0.451
|
|
FEF25–75 (%)
|
65.95 ± 19.73
|
82.69 ± 20.36
|
2.946
|
0.005
|
|
FEF25–75% < 65%
|
12 (57.1%)
|
7 (22.6%)
|
6.449
|
0.011
|
|
CT abnormalitiesc
|
N = 22
|
N = 33
| | |
|
GGO
|
6 (27.3%)
|
2 (6.0%)
|
16.360
|
< 0.001
|
|
Interstitial fibrosis
|
7 (31.8%)
|
0
| | |
|
Others
|
5 (22.7%)
|
1 (3.0%)
| | |
- a, b, c, The number of SARS survivors undertaking different tests
